Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan

ダウンロード数 : ? 件

この文献の参照には次のURLをご利用ください : https://ir.lib.shimane-u.ac.jp/53563

言語	英語
著者	Inoue Daisuke Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3, Anesaki, Ichihara-shi, Chiba, 299-0111, Japan Muraoka Ryoichi Data Science Group, Clinical Development Department, Ajinomoto Pharmaceuticals Co., Ltd., Tokyo, Japan Okazaki Ryo Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3, Anesaki, Ichihara-shi, Chiba, 299-0111, Japan Nishizawa Yoshiki Department of Metabolism, Endocrinology, and Molecular Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan 杉本利嗣
主題	Bisphosphonate; Risedronate; Metabolic syndrome; Life style-related disease; Bone mineral density; Bone turnover markers
掲載誌名	CALCIFIED TISSUE INTERNATIONAL
巻	98
号	2
開始ページ	114
終了ページ	122
ISSN	0171-967X
ISSN（Online）	1432-0827
発行日	2016-02
DOI	10.1007/s00223-015-0071-9
PubMed ID	26466937
出版者	SPRINGER
資料タイプ	学術雑誌論文
部局	医学部
備考	This study was supported by the Joint Development Program of Ajinomoto Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Funding for writing/editorial support was provided by Ajinomoto Pharmaceuticals Co., Ltd.